What is NVAX's market cap?

Novavax, Inc. (NVAX) is a listed stock with a live quote. The latest market cap on this page is $1.8B.

Where is Novavax, Inc. headquartered?

Novavax, Inc. is headquartered in Gaithersburg, MD.

How do I get NVAX news from the API?

Call GET /v1/news?tickers=NVAX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does NVAX news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NVAX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the NVAX price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

NVAX · NASDAQ

Novavax, Inc.

$10.72 +0.05 (+0.47%)

Company overview

Novavax, Inc. is a biotechnology company that discovers, develops, and commercializes vaccines to prevent serious infectious diseases and address pressing health needs. Its pipeline includes NVX-CoV2373, a coronavirus vaccine candidate undergoing two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. The company is also developing an RSV F vaccine in Phase II clinical trial for adults 60 years and older and in Phase I clinical trial for pediatrics. Novavax has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $1.8B
Employees: 952
Headquarters: Gaithersburg, MD
Website: novavax.com
CEO: John Charles Jacobs
Listed: December 5, 1995
P/E: -19.96
Dividend yield: 0.00%

Company financials

Revenue: $596M
Gross profit: $505M
Operating income: -$66.8M
EBITDA: -$57M
Net income: -$87.8M
EPS: -$0.54
Total assets: $1B
Total debt: $295M
Gross margin: 84.64%
Net margin: -14.73%
Earnings yield: -5.01%

Revenue segmentation

By product (FY 2025)

By region (FY 2025)

Showing FY 2025

Price chart

NVAX 1D NASDAQ O10.01H10.67L9.84C10.67+0.99 (+10.23%)Vol5.50M

News

Ticker	Type	Headline	Source	Published
NVAXNovavax, Inc.	Stock news	UPDATE 1-Novavax boosts 2026 revenue forecast as licensing deals pay off	Reuters	Nov 5, 8:28:22 AM ET
NVAXNovavax, Inc.	Press release	Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights	PR Newswire	Nov 5, 8:00:12 AM ET
NVAXNovavax, Inc.	Stock news	Novavax boosts 2026 revenue forecast as licensing deals pay off	Reuters	Nov 5, 8:00:00 AM ET
NVAXNovavax, Inc.	Stock news	Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release	Zacks Investment Research	Oct 29, 11:06:25 AM ET
NVAXNovavax, Inc.	Press release	Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's .	PR Newswire	Oct 29, 9:37:00 AM ET
NVAXNovavax, Inc.	Press release	Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S....	PR Newswire	Oct 29, 8:00:00 AM ET
NVAXNovavax, Inc.	Stock news	Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know	Zacks Investment Research	Oct 26, 6:46:18 PM ET
NVAXNovavax, Inc.	Stock news	Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports	The Motley Fool	Oct 22, 4:45:59 PM ET
NVAXNovavax, Inc.	Stock news	Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors	Zacks Investment Research	Oct 19, 6:46:00 PM ET
NVAXNovavax, Inc.	Stock news	Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened	Defense World	Oct 18, 2:21:06 AM ET
NVAXNovavax, Inc.	Stock news	Novavax shareholder Shah Capital to step back from activist role	Reuters	Oct 16, 5:24:52 PM ET
NVAXNovavax, Inc.	Stock news	Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady	24/7 Wall Street	Oct 16, 12:44:10 PM ET
NVAXNovavax, Inc.	Stock news	Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know	Zacks Investment Research	Oct 13, 6:45:57 PM ET
NVAXNovavax, Inc.	Stock news	Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines	Zacks Investment Research	Oct 12, 12:16:03 PM ET
NVAXNovavax, Inc.	Stock news	Small Cap Stocks To Add to Your Watchlist – October 10th	Defense World	Oct 12, 2:02:57 AM ET
NVAXNovavax, Inc.	Stock news	Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies	24/7 Wall Street	Oct 9, 1:59:42 PM ET
NVAXNovavax, Inc.	Stock news	Novavax (NVAX) Stock Sinks As Market Gains: Here's Why	Zacks Investment Research	Oct 6, 6:45:59 PM ET
NVAXNovavax, Inc.	Stock news	Novavax Stock Falls Back: What's Going On?	Benzinga	Oct 6, 10:18:49 AM ET
NVAXNovavax, Inc.	Stock news	Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher	24/7 Wall Street	Oct 6, 9:56:03 AM ET
NVAXNovavax, Inc.	Stock news	Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?	Zacks Investment Research	Oct 6, 4:15:59 AM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.